Reviewing Kadmon Holdings (KDMN) and The Competition
Kadmon Holdings (NYSE: KDMN) is one of 48 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it contrast to its peers? We will compare Kadmon Holdings to related businesses based on the strength of its institutional ownership, earnings, risk, profitability, dividends, valuation and analyst recommendations.
This table compares Kadmon Holdings and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Kadmon Holdings Competitors||-13,496.16%||-98.93%||-26.22%|
This table compares Kadmon Holdings and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Kadmon Holdings||$26.06 million||-$208.75 million||-2.05|
|Kadmon Holdings Competitors||$563.95 million||$96.15 million||57.92|
Kadmon Holdings’ peers have higher revenue and earnings than Kadmon Holdings. Kadmon Holdings is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Kadmon Holdings has a beta of 2.74, indicating that its stock price is 174% more volatile than the S&P 500. Comparatively, Kadmon Holdings’ peers have a beta of 1.24, indicating that their average stock price is 24% more volatile than the S&P 500.
Insider & Institutional Ownership
28.0% of Kadmon Holdings shares are held by institutional investors. Comparatively, 43.9% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 8.4% of Kadmon Holdings shares are held by company insiders. Comparatively, 15.5% of shares of all “Biopharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of current ratings for Kadmon Holdings and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Kadmon Holdings Competitors||130||797||1737||59||2.63|
Kadmon Holdings presently has a consensus target price of $9.75, indicating a potential upside of 171.59%. As a group, “Biopharmaceuticals” companies have a potential upside of 13.58%. Given Kadmon Holdings’ higher probable upside, equities research analysts clearly believe Kadmon Holdings is more favorable than its peers.
Kadmon Holdings peers beat Kadmon Holdings on 8 of the 12 factors compared.
About Kadmon Holdings
Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company’s portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson’s disease.
Receive News & Stock Ratings for Kadmon Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc. and related stocks with our FREE daily email newsletter.